EGRIFTA
LOE Approachingtesamorelin
BLASUBCUTANEOUSPOWDER
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
EGRIFTA (tesamorelin) is vitro, tesamorelin binds and stimulates human grf receptors with similar potency as the endogenous grf [see clinical pharmacology ()]. First approved in 2010.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EGRIFTA (tesamorelin) is a synthetic growth hormone-releasing factor (GRF) analog administered via subcutaneous injection as a lyophilized powder. It binds to and stimulates GRF receptors on pituitary somatotroph cells to increase endogenous growth hormone synthesis and release, which has both anabolic and lipolytic effects. The drug is indicated for lipodystrophy in HIV-infected patients, where it reduces visceral adipose tissue while improving metabolic parameters.
LOE Approaching
Product is in late-stage lifecycle with modest commercial activity; expect stable but not expanding team size as focus shifts to LOE planning.
Mechanism of Action
vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF [see Clinical Pharmacology ()]. Growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Started Jul 2025
100 enrolled
HIV-1-infectionFrailtyImpaired Physical Function+2 more
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Started Jun 2018
36 enrolled
Peripheral Nerve Injuries
Tesamorelin Effects on Liver Fat and Histology in HIV
Started Jul 2015
61 enrolled
Human Immunodeficiency Virus (HIV)Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.